June 21 2017: In a letter signed by 34 health and consumer groups to the USDA, we asked for stronger action against antibiotic resistance by improving tracking, using fewer antibiotics on farms, and supporting research to keep people safe.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Letter to Secretary Price of HHS Concerning Antimicrobial Resistance
June 21 2017: In a letter signed by 34 health and consumer groups to the HHS, we asked for stronger action against antibiotic resistance by improving tracking, using fewer antibiotics on farms, and supporting research to keep people safe.
Read More »NCHR Public Comments at the FDA’s Safe Use Symposium: A Focus on Outpatient Preventable Adverse Drug Effects
Megan Polanin, June 15 2017: At the FDA’s Safe Use Symposium, the National Center for Health Research emphasized the need for better communication between doctors and patients about drug risks, especially regarding side effects, off-label uses, and how medications may affect people differently based on age, gender, or race. They called on the FDA to make drug labels clearer and more useful to help prevent harmful drug reactions.
Read More »NCHR Remarks to the FDA Science Board on Patient Engagement
The National Center for Health Research tells the FDA it’s important to hear from real patients, not just those backed by drug companies, so that decisions about new medicines and treatments are safer and more fair.
Read More »Letter Opposing Amendments to FDA’s User Fee Program that Weaken Patient Safeguards
June 5, 2017. When an unproven assertion of safety and effectiveness is relied on to market a medical product, the resulting harm may be severe—even life-threatening.
Read More »